A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Update Il y a 4 ans
Reference: NCT01611272

Woman and Man

Extract

To identify the following items through the post marketing surveillance under routine clinical practice after marketing authorization of Brilinta Tablet: the occurrence of unrevealed Serious Adverse Events (SAEs), current status of occurrence of Adverse Events (AEs), the factors that may influence safety and efficacy of the drug.


Inclusion criteria

  • Acute Coronary Syndromes

Links